Hundreds of children in England prescribed weight-loss jabs, figures show
Özet haber: Exclusive: investigation finds prescriptions for children under 12, as experts stress need for specialist supervision and long-term monitoring

Exclusive: investigation finds prescriptions for children under 12, as experts stress need for specialist supervision and long-term monitoring
Hundreds of children in England are receiving prescriptions for GLP-1 medications, including some younger than 12, the Guardian can reveal.
GLP-1 medications were initially developed to help people with type 2 diabetes control their blood sugar levels, but have since become a popular slimming aid, with products such as Wegovy and Mounjaro becoming household names.
While social media is awash with adults who have lost weight with GLP-1s, data shows a number of children are also being prescribed them.
A Guardian investigation has revealed that in the financial year 2025-26 there were 419 prescriptions issued to children under the age of 18, 10 of which were for children under the age of 12.
And in the four months from April to July this year, 341 prescriptions for GLP-1s were issued to children, 15 of whom were under the age of 12.
The figures, obtained from the NHS Business Services Authority through freedom of information requests, relate to prescriptions in England and dispensed in a community setting anywhere in the UK.
However, they do not cover those prescribed and dispensed via private prescriptions, in prisons, and in hospitals, meaning the figures are likely to be a considerable underestimate.
One private clinic for children has previously revealed it has more than 200 patients receiving the jabs. It is also unclear whether the GLP-1 figures reflect medications that are being given primarily for weight loss.
Martin Whyte, a professor of metabolic medicine at the University of Surrey, said the number of prescriptions was still small relative to the scale of childhood obesity, but those taking the drugs needed long-term change to their lifestyles.
He said: “The important thing is that children who start them do so within specialist services, with support for diet, growth and wellbeing, and a plan for the long term.
“That includes regular monitoring of growth and puberty, nutritional intake, mental health and eating behaviours, and side effects. This matters partly because we know weight tends to return when the drugs are stopped, and partly because we still have limited data on use over many years in growing young people.”
The rising use of GLP-1s comes as levels of childhood obesity are increasing. Figures from the National Child Measurement Programme show that 10.7% of reception-year children (ages 4 and 5) are obese, while that rises to 22.8% for children in year 6 (ages 10 and 11).
According to the World Health Organization (WHO), 400 million children and adolescents aged between five and 19 were overweight in 2024, including 170 million living with obesity.
As part of efforts for early intervention, the NHS began piloting Complications from Excess Weight (CEW) clinics from 2021, aimed at children aged two to 16 with severe obesity.



